Cornelis M van Tilburg

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Venues

JCO precision oncology

Neuro-oncology

NPJ precision oncology

Clinical epigenetics

This page only lists publications with an associated author ORCID identifier.

Publications

Martin G McCabe, Didier Frappaz, Louis Chesler, Darren R Hargrave, Donald Williams Parsons, Cornelis M van Tilburg, Gudrun Schleiermacher, John A Hickman, Sally L George
Precision Medicine for Childhood Cancer: Current Limitations and Future Perspectives. JCO precision oncology 8 (2024)
Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Till Milde, Barbara C Jones, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonios Kattamis, Iwona Dachowska-Kalwak, Anna Nilsson, Nicolas U Gerber, Karin P S Langenberg, Bianca Frederika Goemans, Christian Michel Zwaan, Jan J Molenaar, Natalie Jäger, Uta Dirksen, Ruth Witt, Stefan M Pfister, David T W Jones, Dominik T Schneider, Olaf Witt, Cornelis M van Tilburg
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO precision oncology 7 (2023)
Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Till Milde, Barbara C Jones, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonios Kattamis, Iwona Dachowska-Kalwak, Anna Nilsson, Nicolas U Gerber, Karin P S Langenberg, Bianca Frederika Goemans, Christian Michel Zwaan, Jan J Molenaar, Natalie Jäger, Uta Dirksen, Ruth Witt, Stefan M Pfister, David T W Jones, Dominik T Schneider, Olaf Witt, Cornelis M van Tilburg
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO precision oncology 7 (2023)
Nora Jamaladdin, Romain Sigaud, Daniela Kocher, Anna S Kolodziejczak, Leo F Nonnenbroich, Jonas Ecker, Diren Usta, Julia Benzel, Heike Peterziel, Kristian W Pajtler, Cornelis M van Tilburg, Ina Oehme, Olaf Witt, Till Milde
Key pharmacokinetic parameters of 74 pediatric anticancer drugs providing assistance in preclinical studies. Clinical pharmacology and therapeutics (2023)
Emily C Hardin, Simone Schmid, Alexander Sommerkamp, Carina Bodden, Anna-Elisa Heipertz, Philipp Sievers, Andrea Wittmann, Till Milde, Stefan M Pfister, Andreas von Deimling, Svea Horn, Nina A Herz, Michèle Simon, Ashwyn A Perera, Amedeo Azizi, Ofelia Cruz, Sarah Curry, An Van Damme, Miklos Garami, Darren Hargrave, Antonis Kattamis, Barbara Faganel Kotnik, Päivi Maria Lähteenmäki, Katrin Scheinemann, Antoinette Y N Schouten-van Meeteren, Astrid Sehested, Elisabetta Viscardi, Ole Mikal Wormdal, Michal Zapotocky, David S Ziegler, Arend Koch, Pablo Hernáiz Driever, Olaf Witt, David Capper, Felix Sahm, David T W Jones, Cornelis M van Tilburg
LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-oncology (2023)
Romain Sigaud, Thomas Karl Albert, Caroline Hess, Thomas Hielscher, Nadine Winkler, Daniela Kocher, Carolin Walter, Daniel Münter, Florian Selt, Diren Usta, Jonas Ecker, Angela Brentrup, Martin Hasselblatt, Christian Thomas, Julian Varghese, David Capper, Ulrich W Thomale, Pablo Hernáiz Driever, Michèle Simon, Svea Horn, Nina Annika Herz, Arend Koch, Felix Sahm, Stefan Hamelmann, Augusto Faria Andrade, Nada Jabado, Martin Ulrich Schuhmann, Antoinette Y N Schouten-van Meeteren, Eelco Wieger Hoving, Tilman Brummer, Cornelis M van Tilburg, Stefan M Pfister, Olaf Witt, David T W Jones, Kornelius Kerl, Till Milde
MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nature communications 14 (1) (2023)
Florian Selt, Romain Sigaud, Gintvile Valinciute, Philipp Sievers, Julia Zaman, Clara Alco, Simone Schmid, Heike Peterziel, Jessica W Tsai, Romain Guiho, Juan Pedro Martínez-Barbera, Stefan Pusch, Jing Deng, Yifan Zhai, Cornelis M van Tilburg, Martin U Schuhman, Ahmed E L Damaty, Pratiti Bandopadhayay, Christel Herold-Mende, Andreas von Deimling, Stefan M Pfister, Joan Montero, David Capper, Ina Oehme, Felix Sahm, David T W Jones, Olaf Witt, Till Milde
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro-oncology (2022)
Heike Peterziel, Nora Jamaladdin, Dina ElHarouni, Xenia F Gerloff, Sonja Herter, Petra Fiesel, Yannick Berker, Mirjam Blattner-Johnson, Kathrin Schramm, Barbara C Jones, David Reuss, Laura Turunen, Aileen Friedenauer, Tim Holland-Letz, Martin Sill, Lena Weiser, Christopher Previti, Gnanaprakash Balasubramanian, Nicolas U Gerber, Johannes Gojo, Caroline Hutter, Ingrid Öra, Olli Lohi, Antonis Kattamis, Bram de Wilde, Frank Westermann, Stephan Tippelt, Norbert Graf, Michaela Nathrath, Monika Sparber-Sauer, Astrid Sehested, Christof Maria Kramm, Uta Dirksen, Olli Kallioniemi, Stefan M Pfister, Cornelis M van Tilburg, David T W Jones, Jani Saarela, Vilja Pietiäinen, Natalie Jäger, Matthias Schlesner, Dominik T Schneider, Sina Oppermann, Till Milde, Olaf Witt, Ina Oehme
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ precision oncology 6 (1) (2022)
Heike Peterziel, Nora Jamaladdin, Dina ElHarouni, Xenia F Gerloff, Sonja Herter, Petra Fiesel, Yannick Berker, Mirjam Blattner-Johnson, Kathrin Schramm, Barbara C Jones, David Reuss, Laura Turunen, Aileen Friedenauer, Tim Holland-Letz, Martin Sill, Lena Weiser, Christopher Previti, Gnanaprakash Balasubramanian, Nicolas U Gerber, Johannes Gojo, Caroline Hutter, Ingrid Öra, Olli Lohi, Antonis Kattamis, Bram de Wilde, Frank Westermann, Stephan Tippelt, Norbert Graf, Michaela Nathrath, Monika Sparber-Sauer, Astrid Sehested, Christof Maria Kramm, Uta Dirksen, Olli Kallioniemi, Stefan M Pfister, Cornelis M van Tilburg, David T W Jones, Jani Saarela, Vilja Pietiäinen, Natalie Jäger, Matthias Schlesner, Dominik T Schneider, Sina Oppermann, Till Milde, Olaf Witt, Ina Oehme
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ precision oncology 6 (1) (2022)
Heike Peterziel, Nora Jamaladdin, Dina ElHarouni, Xenia F Gerloff, Sonja Herter, Petra Fiesel, Yannick Berker, Mirjam Blattner-Johnson, Kathrin Schramm, Barbara C Jones, David Reuss, Laura Turunen, Aileen Friedenauer, Tim Holland-Letz, Martin Sill, Lena Weiser, Christopher Previti, Gnanaprakash Balasubramanian, Nicolas U Gerber, Johannes Gojo, Caroline Hutter, Ingrid Öra, Olli Lohi, Antonis Kattamis, Bram de Wilde, Frank Westermann, Stephan Tippelt, Norbert Graf, Michaela Nathrath, Monika Sparber-Sauer, Astrid Sehested, Christof Maria Kramm, Uta Dirksen, Olli Kallioniemi, Stefan M Pfister, Cornelis M van Tilburg, David T W Jones, Jani Saarela, Vilja Pietiäinen, Natalie Jäger, Matthias Schlesner, Dominik T Schneider, Sina Oppermann, Till Milde, Olaf Witt, Ina Oehme
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ precision oncology 6 (1) (2022)
Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Schmitt, Kathrin I Foerster, Juergen Burhenne, Walter Emil Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M van Tilburg, David T W Jones, Stefan M Pfister, Deborah Knoerzer, Brent L Kreider, Max Sauter, Kristian W Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde
The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models. Neuro-oncology (2022)
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, Cornelis M van Tilburg, Mirjam Blattner-Johnson, Uta Dirksen, Ingrid Öra, Didier Frappaz, Gudrun Schleiermacher, Stefan M Pfister, Olaf Witt, David T W Jones, Gilles Vassal
NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. JCO precision oncology 5 (2022)
Cornelis M van Tilburg, Elke Pfaff, Kristian W Pajtler, Karin P S Langenberg, Petra Fiesel, Barbara C Jones, Gnana Prakash Balasubramanian, Sebastian Stark, Pascal D Johann, Mirjam Blattner-Johnson, Kathrin Schramm, Nicola Dikow, Steffen Hirsch, Christian Sutter, Kerstin Grund, Arend von Stackelberg, Andreas E Kulozik, Andrej Lissat, Arndt Borkhardt, Richard P Meisel, Dirk Reinhardt, Jan-Henning Klusmann, Gudrun Fleischhack, Stephan Tippelt, Dietrich von Schweinitz, Irene Schmid, Christof Maria Kramm, Andre O von Bueren, Gabriele Calaminus, Peter Vorwerk, Norbert Graf, Frank Westermann, Matthias Fischer, Angelika Eggert, Birgit Burkhardt, Wilhelm Wößmann, Michaela Nathrath, Stefanie Hecker-Nolting, Michael C Frühwald, Dominik T Schneider, Ines B Brecht, Petra Ketteler, Simone Fulda, Ewa Koscielniak, Michael T Meister, Monika Scheer, Simone Hettmer, Matthias Schwab, Roman Tremmel, Ingrid Öra, Caroline Hutter, Nicolas U Gerber, Olli Lohi, Bernarda Kazanowska, Antonios Kattamis, Maria Filippidou, Bianca Frederika Goemans, C Michel Zwaan, Till Milde, Natalie Jäger, Stephan Wolf, David Reuss, Felix Sahm, Andreas von Deimling, Uta Dirksen, Angelika Freitag, Peter Lichter, David T W Jones, Jan J Molenaar, David Capper, Stefan M Pfister
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer discovery 11 (11) (2021)
Diren Usta, Romain Sigaud, Juliane L Buhl, Florian Selt, Viktoria Marquardt, David Pauck, Jennifer Jansen, Stefan Pusch, Jonas Ecker, Thomas Hielscher, Johanna Vollmer, Alexander C Sommerkamp, Tobias Rubner, Darren R Hargrave, Cornelis M van Tilburg, Stefan M Pfister, David T W Jones, Marc Remke, Tilman Brummer, Olaf Witt, Till Milde
A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. Molecular cancer therapeutics 19 (8) (2020)
Cornelis M van Tilburg, Ruth Witt, Melanie Heiss, Kristian W Pajtler, Christoph Plass, Isabel Poschke, Michael Platten, Inga Harting, Oliver Sedlaczek, Angelika Freitag, David Meyrath, Lenka Taylor, Gnana Prakash Balasubramanian, Natalie Jäger, Elke Pfaff, Barbara C Jones, Till Milde, Stefan M Pfister, David T W Jones, Annette Kopp-Schneider, Olaf Witt
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC cancer 20 (1) (2020)
Cornelis M van Tilburg, Till Milde, Ruth Witt, Jonas Ecker, Thomas Hielscher, Angelika Seitz, Jens-Peter Schenk, Juliane L Buhl, Dennis Riehl, Michael C Frühwald, Arnulf Pekrun, Claudia Rossig, Regina Wieland, Christian Flotho, Uwe Kordes, Bernd Gruhn, Thorsten Simon, Christin Linderkamp, Felix Sahm, Lenka Taylor, Angelika Freitag, Jürgen Burhenne, Kathrin I Foerster, Andreas D Meid, Stefan M Pfister, Irini Karapanagiotou-Schenkel, Olaf Witt
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical epigenetics 11 (1) (2019)
Cornelis M van Tilburg, Florian Selt, Felix Sahm, Heidi Bächli, Stefan M Pfister, Olaf Witt, Till Milde
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. Pediatric blood & cancer 65 (3) (2017)

Cornelis M van Tilburg.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Cornelis M van Tilburg